AREV Life Sciences Global Corp. has appointed Kevin Phelps, CPA, as the Chief Operating Officer to facilitate its growth and expansion. Phelps, with over 40 years of experience in biotechnology and business, served in various executive roles, including as CEO and CFO. The company also announced a retention warrant offering for its senior management, including a pricing structure and exercise provisions. Insiders' participation in this offering qualifies as a 'related party transaction' but is exempt from formal valuation. AREV focuses on delivering therapeutic solutions through innovative drug design and collaborations.
AREV Life Sciences Global Corp. (CSE: AREV, OTC: AREVF) has announced its initial research engagement with TransBIOTech, a supported preclinical research organization. This collaboration aims to explore the therapeutic potential of cannabinoids and address public health challenges. Leveraging proprietary extraction technologies, AREV plans to conduct studies on immune modulation and phytomedicinal therapeutics. Initial studies will focus on understanding the pharmacological properties of compounds, with a goal of satisfying regulatory requirements for human studies and eventual commercialization.
AREV Life Sciences Global Corp. has completed its fungi inoculation lab in Coquitlam, focusing on Lion's Mane mushrooms. The company achieves a 10% extraction yield, regarded as exceptional by experts. This milestone enhances revenue streams and positions AREV for potential applications in health products and drug development. Lion's Mane's compounds may offer various health benefits, including brain protection and anti-inflammatory properties. However, human studies are still required to confirm efficacy.
AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) announced new acquisitions and product developments on Feb. 17, 2022. Key appointments include Douglas Sorocco to the scientific advisory committee and IP council, enhancing corporate capacity. The company is focused on its ready-to-use therapeutic food, SUSTAINN, amid a global famine crisis. Additionally, AREV extended its partnership with Strategic Health Resources LLC to gain formulary inclusion for SUSTAINN. The company also issued 100,000 stock options to key personnel at a price of $0.29 each.